Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment

Tyrosine kinase inhibitors (TKIs) have dramatically improved the life expectancy of patients suffering from chronic myeloid leukemia (CML); however, patients will eventually develop resistance to TKI therapy or adverse side effects due to secondary off-target mechanisms associated with TKIs. CML pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Oaxaca, Derrick M., Yang-Reid, Sun Ah, Ross, Jeremy A., Rodriguez, Georgialina, Staniswalis, Joan G., Kirken, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080333/
https://www.ncbi.nlm.nih.gov/pubmed/27444277
http://dx.doi.org/10.1007/s13277-016-5179-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080333/
https://www.ncbi.nlm.nih.gov/pubmed/27444277
http://dx.doi.org/10.1007/s13277-016-5179-7

Ejemplares similares